$1.59
2.58% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US7458481014
Symbol
LUNG

ProLung Inc Stock price

$1.59
-1.09 40.67% 1M
-5.42 77.32% 6M
-5.20 76.58% YTD
-4.11 72.11% 1Y
-20.60 92.83% 3Y
-17.41 91.63% 5Y
-17.41 91.63% 10Y
-17.41 91.63% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.04 2.58%

Key metrics

Basic
Market capitalization
$64.8m
Enterprise Value
$17.7m
Net debt
positive
Cash
$84.2m
Shares outstanding
40.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.7 | 0.6
EV/Sales
0.2 | 0.2
EV/FCF
negative
P/B
0.9
Financial Health
Equity Ratio
52.7%
Return on Equity
-65.7%
ROCE
-45.6%
ROIC
-102.9%
Debt/Equity
0.5
Financials (TTM | estimate)
Revenue
$90.6m | $98.8m
EBITDA
$-55.7m | $-38.8m
EBIT
$-56.9m | $-63.6m
Net Income
$-56.9m | $-63.6m
Free Cash Flow
$-32.0m
Growth (TTM | estimate)
Revenue
18.2% | 17.9%
EBITDA
0.7% | 28.8%
EBIT
1.1% | -13.6%
Net Income
1.6% | -12.8%
Free Cash Flow
11.8%
Margin (TTM | estimate)
Gross
73.1%
EBITDA
-61.5% | -39.3%
EBIT
-62.9%
Net
-62.9% | -64.4%
Free Cash Flow
-35.3%
More
EPS
$-1.4
FCF per Share
$-0.8
Short interest
4.9%
Employees
291
Rev per Employee
$290.0k
Show more

Is ProLung Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

ProLung Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a ProLung Inc forecast:

9x Buy
75%
3x Hold
25%

Analyst Opinions

12 Analysts have issued a ProLung Inc forecast:

Buy
75%
Hold
25%

Financial data from ProLung Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
91 91
18% 18%
100%
- Direct Costs 24 24
23% 23%
27%
66 66
16% 16%
73%
- Selling and Administrative Expenses 105 105
7% 7%
116%
- Research and Development Expense 18 18
10% 10%
20%
-56 -56
1% 1%
-61%
- Depreciation and Amortization 1.25 1.25
18% 18%
1%
EBIT (Operating Income) EBIT -57 -57
1% 1%
-63%
Net Profit -57 -57
2% 2%
-63%

In millions USD.

Don't miss a Thing! We will send you all news about ProLung Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ProLung Inc Stock News

Neutral
The Motley Fool
13 days ago
Pulmonx (LUNG) Q2 Revenue Rises 15%
Neutral
Seeking Alpha
13 days ago
Pulmonx Corporation (NASDAQ:LUNG ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 AM ET Company Participants Mehul Joshi - Chief Financial Officer Steven S. Williamson - CEO, President & Director Conference Call Participants Frank James Takkinen - Lake Street Capital Markets, LLC, Research Division Frederick Allen Wise - Stifel, Nicolaus & Company, Incorporated, Research Division Jeremy Fe...
Neutral
GlobeNewsWire
13 days ago
REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2025 ended June 30, 2025.
More ProLung Inc News

Company Profile

Pulmonx Corp. provides interventional pulmonology, planning tools, and treatments for obstructive lung diseases. It carries out its operations in the following geographical locations: Europe, Middle East and Africa (EMEA), Asia Pacific, Other International, and United States. It offers the Zephyr Endobronchial Valve, an implantable device used to occlude all airways feeding the hyperinflated lobe of a lung that is most diseased with emphysema. It also offers StratX Lung Analysis, a platform designed to treat severe emphysema, and the Chartis Assessment System, a pulmonary assessment system. The company was founded by Rodney C. Perkins and is headquartered in Redwood City, CA.

Head office United States
CEO Steven Williamson
Employees 291
Founded 1995
Website pulmonx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today